OBI Pharma, Inc.

TPEX:4174 Stock Report

Market Cap: NT$13.1b

OBI Pharma Past Earnings Performance

Past criteria checks 0/6

OBI Pharma's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been declining at an average rate of 6.7% per year.

Key information

-2.6%

Earnings growth rate

1.8%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate-6.7%
Return on equity-67.0%
Net Margin-3,028.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

OBI Pharma (GTSM:4174) Shareholders Booked A 69% Gain In The Last Year

Mar 12
OBI Pharma (GTSM:4174) Shareholders Booked A 69% Gain In The Last Year

Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money

Jan 18
Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money

If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82%

Nov 26
If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82%

Revenue & Expenses Breakdown

How OBI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:4174 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2470-2,1073171,751
30 Jun 2458-2,1553281,817
31 Mar 2449-1,2053271,821
31 Dec 2342-1,0463191,697
30 Sep 2324-1,1003211,853
30 Jun 2313-9203051,866
31 Mar 235-1,6723011,799
31 Dec 225-1,6143101,773
30 Sep 227-1,5952781,767
30 Jun 228-1,5322681,577
31 Mar 2216-1,6052621,547
31 Dec 2119-1,5312411,450
30 Sep 2195-1,3412691,262
30 Jun 2194-1,3972861,242
31 Mar 21145-1,2952881,185
31 Dec 20141-1,3782901,310
30 Sep 2067-1,5193221,403
30 Jun 2066-1,4602941,378
31 Mar 206-1,5083101,403
31 Dec 196-1,4073131,257
30 Sep 191-1,3013211,137
30 Jun 191-1,3953251,236
31 Mar 191-1,1733061,162
31 Dec 1813-1,2223091,127
30 Sep 1813-1,1772911,020
30 Jun 1813-1,098320897
31 Mar 1813-1,238343868
31 Dec 170-1,379341849
30 Sep 170-1,298331903
30 Jun 170-1,329326873
31 Mar 1792-1,166330800
31 Dec 1692-1,110345859
30 Sep 1692-1,093359755
30 Jun 1692-860369664
31 Mar 160-916341628
31 Dec 150-941415648
30 Sep 150-868343645
30 Jun 150-885351568
31 Mar 150-925322641
31 Dec 140-667227485
30 Sep 140-617243413
30 Jun 140-565181418
31 Mar 140-453161320

Quality Earnings: 4174 is currently unprofitable.

Growing Profit Margin: 4174 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4174 is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.

Accelerating Growth: Unable to compare 4174's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4174 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).

Return on Equity

High ROE: 4174 has a negative Return on Equity (-66.97%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:28
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OBI Pharma, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pinghan HsiehCapital Securities Corporation
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.
Yijun ChenSinoPac Securities Investment Service